Following treatment with Promacta (Revolade, eltrombopag olamine) a maximum response (increase in platelet counts) was reached at approximately two weeks, according to the results of clinical trials.
Promacta is a thrombopoietin receptor agonist that is used to increase low blood platelet counts (thrombocytopenia) in certain people with chronic immune thrombocytopenia (ITP) and severe aplastic anemia.